Pneumoconiosis due to other dust containing silica (silicosis)
ICD-10 Code: J62.8 · Body Part: Head/Brain (TBI)
QME Evaluation Process
PFTs (spirometry, DLCO, lung volumes), chest CT, silica exposure history documentation. Chapter 5 respiratory impairment.
Typical Impairment Rating
10-65% WPI depending on disease stage and PFT impairment
AMA Guides Edition
5th Edition
Common Treatments
Related Conditions
Body Part Guide
Head/Brain (TBI) Evaluation Guide
Impairment rating methods, common conditions, and QME evaluation protocols
QME Specialties for Pneumoconiosis due to other dust containing silica (silicosis)
Find a QME Specialist
Browse QME-certified physicians who evaluate pneumoconiosis due to other dust containing silica (silicosis) and related head/brain (tbi) conditions in California.
Browse Neurology Physicians →Frequently Asked Questions
What is Pneumoconiosis due to other dust containing silica (silicosis) (J62.8)?
Pneumoconiosis due to other dust containing silica (silicosis) is an ICD-10 diagnosis code (J62.8) classified under Respiratory conditions. It affects the Head/Brain (TBI) and is commonly encountered in California workers' compensation claims. QME physicians evaluate this condition using AMA Guides 5th Edition protocols.
How is J62.8 rated for impairment?
The typical whole person impairment (WPI) range for Pneumoconiosis due to other dust containing silica (silicosis) is 10-65% WPI depending on disease stage and PFT impairment. The exact rating depends on clinical findings, imaging, and the evaluation method (DRE or ROM) chosen by the QME physician per AMA Guides 5th Edition.
What is the QME evaluation process for J62.8?
PFTs (spirometry, DLCO, lung volumes), chest CT, silica exposure history documentation. Chapter 5 respiratory impairment.
What treatments are common for Pneumoconiosis due to other dust containing silica (silicosis)?
Common treatments for Pneumoconiosis due to other dust containing silica (silicosis) include Exposure cessation, Pulmonary rehabilitation, Supplemental oxygen, Lung transplant for end-stage. Treatment appropriateness and outcomes are considered during the QME evaluation when determining permanent and stationary status and apportionment.